Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
05/2003
05/30/2003WO2002041871A9 Composition comprising an imexon or derivatives thereof and lipids
05/30/2003WO2002031025A9 Biodegradable poly(beta-amino esters) and uses thereof
05/30/2003WO2002020090A3 Pharmaceutical compositions
05/30/2003WO2001080823A3 Composition exhibiting enhanced formulation stability and delivery of tropical active ingredients
05/30/2003CA2503669A1 New anti-asthmatic drug (asmakure) from indigenous herbs to cure the disease asthma
05/30/2003CA2468018A1 Micronized film-forming powder comprising an active substance
05/30/2003CA2467908A1 Mfg-e8-l regulates phagocytic removal of apoptotic cells by macrophages
05/30/2003CA2467559A1 Topical delivery of codrugs
05/30/2003CA2467549A1 Use of an ascomycin for the treatment of blepharitis
05/30/2003CA2466986A1 Pharmaceutical formulation comprising bicalutamide
05/30/2003CA2466982A1 Pharmaceutical compositions in particulate form
05/30/2003CA2465779A1 Compositions for sustained action product delivery
05/30/2003CA2464867A1 Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes
05/30/2003CA2463250A1 Edible film
05/30/2003CA2463179A1 Bioerodible poly(ortho esters) containing amine groups, and block copolymers containing them
05/30/2003CA2413224A1 Aqueous solution of ascorbic acid and method for producing same
05/29/2003US20030100865 Implantable drug delivery stents
05/29/2003US20030100852 Adhesive preparation for external use
05/29/2003US20030100694 Hydrophilic polymers and methods of preparation
05/29/2003US20030100612 Aqueous solution of arginine and ibuprofen for the treatment of pain, inflammation and fever
05/29/2003US20030100611 Delivery of gabapentin in a gastric retained dosage form for the treatment of epilepsy and other diseases
05/29/2003US20030100610 Omega -3 series polyunsaturated fatty acids are selected from eicosapentanoic acid and/or docosahexaenoic acid and/or pharmaceutically acceptable derivative
05/29/2003US20030100609 Orally ingesting a quantity of calcium formate sufficient to improve calcium balance or retention
05/29/2003US20030100602 Appetite stimulation and reduction of weight loss in patients suffering from symptomatic hiv infection
05/29/2003US20030100600 Method for treating atherosclerosis or restenosis using microtubule stabilizing agent
05/29/2003US20030100595 Oral dosage form of a sulfonamide prodrug
05/29/2003US20030100574 Tricyclic 3,4-propinoperhydropurines; uses thereof for blocking neuronal transmission
05/29/2003US20030100568 Polymorphic form of itraconazole
05/29/2003US20030100566 Sustained release ranolazine formulations
05/29/2003US20030100551 Production of apoptotic films for direct contact with tumors
05/29/2003US20030100511 Contacting bone marrow or blood with glutamyl-S(benzyl)cysteinyl-R- phenyl glycine diethyl ester to stimulate hematopoiesis, protect hematopoietic cells from damage caused by radiation or chemotherapy
05/29/2003US20030100509 Injectable solution of an LHRH antagonist
05/29/2003US20030100493 Emergency sublingual administration of statins or HMG-CoA reductase inhibitors to a mammal for therapy of impending or catastrophic cardiovascular events, neurovascular events, deep venous thrombosis and embolization; myocardial infarctions
05/29/2003US20030100115 Killing cells that lack tumor suppressor proteins; obtain cells, transform with preferential single stranded nucleotide sequence, monitor viability of cells
05/29/2003US20030099763 Shaped microcomponent via reactive conversion of biologically-derived microtemplates
05/29/2003US20030099747 Thickened oil compositions of edible oil
05/29/2003US20030099741 Process for preparing chewing gum containing a nutritional supplemental
05/29/2003US20030099740 For oral hygiene and particularly for the removal and the prevention of the formation of dental plaque
05/29/2003US20030099730 Nutritional supplement and methods of using it
05/29/2003US20030099726 Medicine comprises Echinacea phytochemicals and benzalkonium chloride in a sterile water solution; for therapy
05/29/2003US20030099725 For therapy and prophylaxis of cancers especially cancer of lung, esophagus, stomach, oral cavity and prostate as well as for therapy of Helicobacter pylori infection; useful as adjuncts to conventional surgery or radiotherapy
05/29/2003US20030099718 Nanocrystalline antimicrobial metals (noble metals)formed with atomic disorder are capable of releasing highly active clusters of the antimicrobial metal sufficient to cause microbiocidal effect; anti-inflammatory activity
05/29/2003US20030099715 Coated pellets of granulated particles containing a drug are charcterized in that a bad taste of the drug when taken by patient is reduced or eliminated, and these pellets also contain an organic carboxylic acid and/or a surfactant
05/29/2003US20030099714 Co-lyophilizing one or more peptides or peptide analogues, which are able to adopt an amphipathic conformation and one or more lipids in a solvent system to form a peptide/lipid product, which can be rehydrated to form the complex
05/29/2003US20030099711 Sustained release preparations
05/29/2003US20030099710 Granule modulating hydrogel system
05/29/2003US20030099709 Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
05/29/2003US20030099708 Printing or dispensing a suspension such as three-dimensional printing of dosage forms
05/29/2003US20030099707 Antifungal product, use and formulation thereof
05/29/2003US20030099706 Antiviral product, use and formulation thereof
05/29/2003US20030099705 Sustained release ranolazine formulations
05/29/2003US20030099704 Controlled release oxycodone compositions
05/29/2003US20030099703 Drug-containing solid dispersion having improved solubility
05/29/2003US20030099702 Pharmaceutical excipient having improved compressibility
05/29/2003US20030099701 Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
05/29/2003US20030099700 Orodispersible tablets, able to disintegrate in buccal cavity upon contact with saliva by formation of an easy-to-swallow suspension, in less than 60 seconds, containing fexofenadine or its salt in the form of a coated granule, and excipients
05/29/2003US20030099699 Storage stable thyroxine active drug formulations and methods for their production
05/29/2003US20030099698 Storage stable thyroxine active drug formulations and methods for their production
05/29/2003US20030099697 Amphoteric liposomes and their use
05/29/2003US20030099695 Stabilised oversaturated transdermal therapeutical matrix systems
05/29/2003US20030099694 Method for the improvement of transport across adaptable semi-permeable barriers
05/29/2003US20030099692 Oral film which contains starch as main component; useful for delivering a variety of agents to humans and other animals
05/29/2003US20030099691 Films containing starch
05/29/2003US20030099690 Rapidly soluble film preparation
05/29/2003US20030099678 Method and topical formulation for treating skin conditions associated with aging
05/29/2003US20030099675 Comprising 9-90% by weight monoglyceride compound, 0.01-90% by weight emulsifier, 0-50% by weight water-insoluble material, 0-90.9% by weight of organic solvent; drug delivery
05/29/2003US20030099666 Gum resin as a carrier for topical application of pharmacologically active agents
05/29/2003US20030099659 Comprises glycerides for mucosal administration; provides enhanced adhesion and absorption
05/29/2003US20030099656 Monoclonal antibodies to the ClfA protein and method of use in treating or preventing infections
05/29/2003US20030099606 Iodinating an strong base anion exchange resin with iodine or an iodine compound; abosorbing through the pores of ion exchange resin
05/29/2003US20030099601 Inhalation lung surfactant therapy
05/29/2003US20030099600 Metalloproteinase inhibitors for the treatment of respiratory diseases
05/29/2003US20030099599 Antibiotic spray
05/28/2003EP1314776A1 Optimised pellet formulations
05/28/2003EP1314743A2 Low amylose and adipate crosslinked tapioca starch
05/28/2003EP1314437A1 Stabilized antibody-containing preparations
05/28/2003EP1314436A4 Antiviral agent in the form of nose drops
05/28/2003EP1314436A1 Antiviral agent in the form of nose drops
05/28/2003EP1314428A1 Oct preparations
05/28/2003EP1314424A1 Seamless soft capsule preparations containing dihydrobenzofuran derivatives
05/28/2003EP1314422A2 Orally disintegrating solid preparations and processes for the production thereof
05/28/2003EP1313820A2 Adhesive blends comprising hydrophilic and hydrophobic pressure sensitive adhesives
05/28/2003EP1313772A1 New cross-linked derivatives of hyaluronic acid
05/28/2003EP1313574A1 Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same
05/28/2003EP1313525A2 Apparatus for treatment of chronic obstructive pulmonary disease and associated method
05/28/2003EP1313511A2 Testosterone ester formulation for human use
05/28/2003EP1313510A2 Novel pharmaceutical composition
05/28/2003EP1313504A2 Methods and compositions for inhibiting angiogenesis
05/28/2003EP1313489A2 Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
05/28/2003EP1313484A2 Pharmaceutical formulation of salmeterol and fluticasone propionate
05/28/2003EP1313482A1 Pharmaceutical composition and method for treating hypogonadism
05/28/2003EP1313481A1 Pharmaceutical composition comprising condensed indole compound
05/28/2003EP1313474A2 Paroxetine compositions and processes for making the same
05/28/2003EP1313473A2 Sustained release formulations for growth hormone secretagogues
05/28/2003EP1313472A1 Method for reducing or eliminating smoking
05/28/2003EP1313467A2 Novel pharmaceutical composition for administering n-0923
05/28/2003EP1313466A1 Bimodal emulsions of taxanes and butyrate polyalcohol esters
05/28/2003EP1313457A1 Transdermal therapeutic system for releasing venlafaxine
05/28/2003EP1313456A2 Intradermal-penetration agents for topical local anesthetic administration
05/28/2003EP1313455A2 Controlled and sustained release properties of polyelectrolyte multilayer capsules
1 ... 2135 2136 2137 2138 2139 2140 2141 2142 2143 2144 2145 2146 2147 2148 2149 2150 2151 2152 2153 2154 2155 ... 2991